一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Blood >>article
Blood

Blood

IF: 21
Download PDF

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.

Published:3 March 2016 DOI: 10.1182/blood-2015-04-640920 PMID: 26675347
Natalie M Czuczman,?Matthew J Barth,?Juan Gu,?Vishala Neppalli,?Cory Mavis,?Sarah E Frys,?Qiang Hu,?Song Liu,?Pavel Klener,?Petra Vockova,?Myron S Czuczman,?Francisco J Hernandez-Ilizaliturri

Abstract

Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and inevitable development of refractory disease, stressing the need to develop alternative therapeutic strategies. To this end, we evaluated pevonedistat (MLN4924), a novel potent and selective NEDD8-activating enzyme inhibitor in a panel of MCL cell lines, primary MCL tumor cells, and 2 distinct murine models of human MCL. Pevonedistat exposure resulted in a dose-, time-, and caspase-dependent cell death in the majority of the MCL cell lines and primary tumor cells tested. Of interest, in the MCL cell lines with lower half-maximal inhibitory concentration (0.1-0.5 μM), pevonedistat induced G1-phase cell cycle arrest, downregulation of Bcl-xL levels, decreased nuclear factor (NF)-κB activity, and apoptosis. In addition, pevonedistat exhibited additive/synergistic effects when combined with cytarabine, bendamustine, or rituximab. In vivo, as a single agent, pevonedistat prolonged the survival of 2 MCL-bearing mouse models when compared with controls. Pevonedistat in combination with rituximab led to improved survival compared with rituximab or pevonedistat monotherapy. Our data suggest that pevonedistat has significant activity in MCL preclinical models, possibly related to effects on NF-κB activity, Bcl-xL downregulation, and G1 cell cycle arrest. Our findings support further investigation of pevonedistat with or without rituximab in the treatment of MCL.

Substances (8)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Cytarabine 147-94-4 C9H13N3O5 792 suppliers $5.00-$1025.00
Pevonedistat 905579-51-3 C21H25N5O4S 201 suppliers $27.00-$4735.50
Rituximab 174722-31-7 C6416H9874N1688O1987S44 131 suppliers Inquiry
JEKO-1 human mantle cell lymphoma cells 69 suppliers Inquiry
Bendamustine 97832-05-8 C16H21Cl2N3O2.HCl 42 suppliers Inquiry
Bcl-XL 28 suppliers Inquiry
Ubiquitin-activating enzyme E1C 10 suppliers Inquiry
THP1-Blue NF-κB Cells 4 suppliers Inquiry

Similar articles

IF:4.6

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor.

Clinical Pharmacokinetics Neeraj Gupta, Michael J Hanley,etc Published: 1 August 2023
IF:5.3

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer.

ACS Applied Nano Materials Jennifer Ferris, Margarita Espona-Fiedler,etc Published: 21 July 2020
阿克陶县| 宜宾县| 陆河县| 扎囊县| 大关县| 芦山县| 凌云县| 合肥市| 吴桥县| 安顺市| 洪湖市| 阳城县| 贡嘎县| 绍兴县| 会宁县| 台江县| 明水县| 张掖市| 永丰县| 甘谷县| 抚顺县| 海丰县| 禄劝| 连江县| 白朗县| 额尔古纳市| 公安县| 若羌县| 青田县| 丹江口市| 古浪县| 体育| 呼玛县| 天长市| 临沭县| 柘城县| 屯昌县| 广安市| 凌云县| 泸州市| 大新县|